When IPIX signs a deal of some type w/ a BP, would it be safe to assume that the running of the clinical trial for that particular indication (or drug platform if a whole drug was licensed, which I doubt) will transfer to the BP at that time? Has anyone ever heard of a reverse clause in such a deal where if the BP is running the trial and it fails, then they relinquish all rights to the drug/indication and it reverts back to IPIX? Just covering all the bases so no funny business could be played to keep our products off the market. I know it borders on being paranoid, but the values being bantered about make me believe such oddball clauses should be considered.
